| 1. |
周賢慧, 彭佳欣, 鄧文倩, 等. 厚脈絡膜病變的研究進展[J]. 中華眼底病雜志, 2024, 40(10): 803-807. DOI: 10.3760/cma.j.cn511434-20240424-00167.Zhou XH, Peng JX, Deng WQ, et al. Research progress of pachychoroid spectrum disorders[J]. Chin J Ocul Fundus Dis, 2024, 40(10): 803-807. DOI: 10.3760/cma.j.cn511434-20240424-00167.
|
| 2. |
Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders[J/OL]. Prog Retin Eye Res, 2021, 86: 100973[2021-05-21]. https://pubmed.ncbi.nlm.nih.gov/34029721/. DOI: 10.1016/j.preteyeres.2021.100973.
|
| 3. |
惠延年. 盤周厚脈絡膜綜合征: 厚脈絡膜疾病譜的新病種[J]. 國際眼科雜志, 2023, 23(1): 1-3. DOI: 10.3980/j.issn.1672-5123.2023.1.01.Hui YN. Peripapillary pachychoroid syndrome: a novel entity of pachychoroid disease spectrum[J]. Int Eye Sci, 2023, 23(1): 1-3. DOI: 10.3980/j.issn.1672-5123.2023.1.01.
|
| 4. |
惠延年. 中心性漿液性脈絡膜視網膜病變: 黃斑病, 還是脈絡膜病[J]. 國際眼科雜志, 2025, 25(1): 10-12. DOI: 10.3980/j.issn.1672-5123.2025.1.02.Hui YN. Central serous chorioretinopathy: macular disease, or choroidal disease[J]. Int Eye Sci, 2025, 25(1): 10-12. DOI: 10.3980/j.issn.1672-5123.2025.1.02.
|
| 5. |
Valsecchi N, Ibrahim MN, Hasan N, et al. Volumetric choroidal biomarkers in central serous chorioretinopathy using swept-source optical coherence tomography: a deep learning approach[J/OL]. Graefe's Arch Clin Exp Ophthalmol, 2025, 2025: E1(2025-10-30)[2026-01-05]. https://pubmed.ncbi.nlm.nih.gov/41165808/. DOI: 10.1007/s00417-025-07014-1. [published online ahead of print].
|
| 6. |
Nouri H, Hasan N, Abtahi SH, et al. Deep learning in central serous chorioretinopathy[J]. Surv Ophthalmol, 2026, 71(2): 718-748. DOI: 10.1016/j.survophthal.2025.07.011.
|
| 7. |
Castro R, Kattan E, Retamal J, et al. Venous congestion from a vascular waterfall perspective: reframing congestion as a dynamic Starling resistor phenomenon[J/OL]. Intensive Care Med Exp, 2025, 13(1): 119[2025-11-24]. https://pubmed.ncbi.nlm.nih.gov/41284176/. DOI: 10.1186/s40635-025-00828-7.
|
| 8. |
Koizumi H, Imanaga N, Terao N. Central serous chorioretinopathy and the sclera: what we have learned so far[J]. Jpn J Ophthalmol, 2024, 68(5): 419-428. DOI: 10.1007/s10384-024-01101-2.
|
| 9. |
Cardillo Piccolino F, Arrigo A, Forte P, et al. Intraocular pressure and ocular perfusion pressure in central serous chorioretinopathy[J]. Am J Ophthalmol, 2025, 280: 414-422. DOI: 10.1016/j.ajo.2025.08.045.
|
| 10. |
Kanadani FN, Figueiredo CR, Miranda RM, et al. Ocular perfusion pressure and pulsatile ocular blood flow in normal and systemic hypertensive patients[J]. J Curr Glaucoma Pract, 2015, 9(1): 16-19. DOI: 10.5005/jp-journals-10008-1177.
|
| 11. |
張靈麗, 李華, 鄔羽飛, 等. 鹽皮質激素受體拮抗劑治療慢性中心性漿液性脈絡膜視網膜病變的研究進展[J]. 中華眼底病雜志, 2019, 35(4): 413-417. DOI: 10.3760/cma.j.issn.1005-1015.2019.04.024.Zhang LL, Li H, Wu YF, et al. An update on evidence for mineralocorticoid receptor antagonist in the treatment of central serous retinopathy[J]. Chin J Ocul Fundus Dis, 2019, 35(4): 413-417. DOI: 10.3760/cma.j.issn.1005-1015.2019.04.024.
|
| 12. |
?akmak A?, Atalay E, Irgat SG, et al. Systemic and ocular determinants of mean ocular perfusion pressure in a population-based sample[J]. Jpn J Ophthalmol, 2020, 64(3): 392-397. DOI: 10.1007/s10384-020-00728-1.
|
| 13. |
Cheung CMG, Dansingani KK, Koizumi H, et al. Pachychoroid disease: review and update[J]. Eye (Lond), 2025, 39(5): 819-834. DOI: 10.1038/s41433-024-03253-4.
|
| 14. |
Kong M, Han SY, Song YM, et al. Comprehensive analysis of pachyvessel morphology in central serous chorioretinopathy using multimodal imaging[J/OL]. Sci Rep, 2025, 15: 27553[2025-07-29]. https://pubmed.ncbi.nlm.nih.gov/40730647/. DOI: 10.1038/s41598-025-12718-9.
|
| 15. |
Battista M, Checchin L, Sacconi R, et al. Large choroidal vessels as a risk factor for idiopathic choroidal neovascularization[J]. Ophthalmic Surg Lasers Imaging Retina, 2025, 56(11): 673-680. DOI: 10.3928/23258160-20250812-02.
|
| 16. |
Miyara Y, Terao N, Imanaga N, et al. Association between choroidal vascular hyperpermeability and vortex vein anastomoses in central serous chorioretinopathy[J/OL]. Ophthalmol Sci, 2025, 6(1): 100901[2025-08-05]. https://pubmed.ncbi.nlm.nih.gov/41030827/. DOI: 10.1016/j.xops.2025.100901.
|
| 17. |
Tao M, Lan T, Zhu Y, et al. Characteristics of vortex vein in healthy eyes and fundus diseases imaged by ultra-widefield OCTA[J]. Graefe's Arch Clin Exp Ophthalmol, 2025, 263(10): 2797-2808. DOI: 10.1007/s00417-025-06907-5.
|
| 18. |
Luo Z, Xu Y, Xiong X, et al. Characterization of vortex vein drainage system in healthy individuals imaged by ultra-widefield optical coherence tomography angiography[J/OL]. Transl Vis Sci Technol, 2024, 13(9): 19[2024-09-03]. https://pubmed.ncbi.nlm.nih.gov/39292469/. DOI: 10.1167/tvst.13.9.19.
|
| 19. |
Kabiri P, Künzel S, Ashraf-Vaghefi S, et al. Changes in choroidal vessel morphology associated with fluid leakage in central serous chorioretinopathy; a comparison of OCTA and ICGA[J]. Graefe's Arch Clin Exp Ophthalmol, 2025, 263(11): 3065-3072. DOI: 10.1007/s00417-025-06918-2.
|
| 20. |
Bosic V, Fraenkel D, Mudassar H, et al. Central serous chorioretinopathy imaging biomarkers as potential indicators of response to subthreshold nanosecond laser[J]. Indian J Ophthalmol, 2025, 73(9): 1344-1349. DOI: 10.4103/IJO.IJO_450_25.
|
| 21. |
Kishi S, Matsumoto H. A new insight into pachychoroid diseases: remodeling of choroidal vasculature[J]. Graefe's Arch Clin Exp Ophthalmol, 2022, 260(11): 3405-3417. DOI: 10.1007/s00417-022-05687-6.
|
| 22. |
Chang-Wolf JM, Pauleikhoff LJB, Ruiters C, et al. Choroidal vascular hyperpermeability patterns in central serous chorioretinopathy correlate with microperimetry: CERTAIN study report 4[J/OL]. Acta Ophthalmol, 2019, 2019: E1(2025-09-17)[2026-01-15]. https://pubmed.ncbi.nlm.nih.gov/40960367/. DOI: 10.1111/aos.17588. [published online ahead of print].
|
| 23. |
Tatti F, Loiudice P, Mangoni L, et al. Flat irregular pigment epithelium detachments in chronic central serous chorioretinopathy: a focus on choroidal changes[J]. Eye (Lond), 2025, 39(17): 3063-3069. DOI: 10.1038/s41433-025-04026-3.
|
| 24. |
Viggiano P, Boscia G, Sadeghi E, et al. Pachychoroid disease spectrum: how multimodal imaging and OCT angiography have improved our knowledge[J/OL]. Prog. Retin. Eye Res, 2025, 107: 101372[2025-05-23]. https://pubmed.ncbi.nlm.nih.gov/40414595/. DOI: 10.1016/j.preteyeres.2025.101372.
|
| 25. |
Funatsu R, Terasaki H, Sonoda S, et al. Structural changes in vortex vein ampullae in eyes with pachychoroid-spectrum disorder[J/OL]. Sci Rep, 2025, 15(1): 11125[2025-04-01]. https://pubmed.ncbi.nlm.nih.gov/40169627/. DOI: 10.1038/s41598-024-82731-x.
|
| 26. |
Carlà MM, Couturier A, Mottola F, et al. The influence of scleral buckle on choroidal architecture: an unexplored link with the spectrum of acquired overload choroidopathy?[J]. Surv Ophthalmol, 2025, 70(6): 1181-1190. DOI: 10.1016/j.survophthal.2025.07.002.
|
| 27. |
Prabhakaran P, Pradeep BC, Pandit AD, et al. Evaluation of anterior scleral thickness in eyes with central serous chorioretinopathy[J]. Indian J Ophthalmol, 2025, 73(6): 833-836. DOI: 10.4103/IJO.IJO_3116_24.
|
| 28. |
Nitzan I, Kubovsky S, Shemesh N, et al. Association of migraine with increased risk of central serous chorioretinopathy: a retrospective cohort study[J]. Am J Ophthalmol, 2026, 282: 60-68. DOI: 10.1016/j.ajo.2025.10.029.
|
| 29. |
Chawla R. Pathogenesis of central serous choroidopathy: a novel hypothesis[J]. Indian J Ophthalmol, 2024, 72(10): 1387-1389. DOI: 10.4103/IJO.IJO_2188_24.
|
| 30. |
劉培, 杜利平, 金學民. 中心性漿液性脈絡膜視網膜病變研究進展[J]. 中華實驗眼科雜志, 2025, 43(8): 754-760. DOI: 10.3760/cma.j.cn115989-20221206-00574.Liu P, Du LP, Jin XM. Research advances in central serous chorioretinopathy[J]. Chin J Exp Ophthalmol, 2025, 43(8): 754-760. DOI: 10.3760/cma.j.cn115989-20221206-00574.
|
| 31. |
Matsumoto H, Hoshino J, Nakamura K, et al. Reduction in choroidal thickness associated with the progression of pachychoroid spectrum diseases[J]. Jpn J Ophthalmol, 2025, 69(6): 902-910. DOI: 10.1007/s10384-025-01230-2.
|
| 32. |
Valsecchi N, Sadeghi E, Davis E, et al. Three-dimensional choroidal vessels assessment in fellow eyes of patients with central serous chorioretinopathy[J/OL]. Transl Vis Sci Technol, 2025, 14(9): 10[2025-09-02]. https://pubmed.ncbi.nlm.nih.gov/40919871/. DOI: 10.1167/tvst.14.9.10.
|
| 33. |
Chong YJ, Chong Teo KY, Gilead N, et al. Regional variability in choroidal vascularity index and association with intervortex anastomoses in polypoidal choroidal vasculopathy[J]. Retina, 2025, 45(11): 2027-2034. DOI: 10.1097/IAE.0000000000004590.
|
| 34. |
Yoon JM, Lim JY, Noh H, et al. Deep learning-based automated classification of choroidal layers in en face swept-source optical coherence tomography images[J/OL]. BMC Ophthalmol, 2025, 25(1): 344[2025-07-01]. https://pubmed.ncbi.nlm.nih.gov/40597023/. DOI: 10.1186/s12886-025-04170-0.
|
| 35. |
Kim RY, Hwang BE, Kim JY, et al. Changes in choriocapillaris blood flow following half-fluence, full-dose photodynamic therapy (PDT) and half-fluence, half-dose PDT in patients with central serous chorioretinopathy: a quantitative analysis of early post-treatment alterations[J/OL]. Photodiagnosis Photodyn Ther, 2025, 56: 105255[2025-10-20]. https://pubmed.ncbi.nlm.nih.gov/41115602/. DOI: 10.1016/j.pdpdt.2025.105255.
|
| 36. |
Viggiano P, Demirel S, Petruzzella G, et al. Choriocapillaris flow in two different patterns of exudative type 1 macular neovascularization[J]. Eye (Lond), 2025, 39(3): 556-562. DOI: 10.1038/s41433-024-03587-z.
|
| 37. |
Hao X, Pu J, Li M, et al. Evaluation of choroidal vein distribution pattern and choroidal vessel parameters in patients with central serous chorioretinopathy using widefield ICGA and widefield OCTA[J]. Am J Ophthalmol, 2025, 279: 193-204. DOI: 10.1016/j.ajo.2025.07.033.
|
| 38. |
Kim YJ, Sivaprasad S, Aslam T, et al. Treatment of central serous chorioretinopathy: new options for an old disease[J]. Eye (Lond), 2025, 39(12): 2375-2388. DOI: 10.1038/s41433-025-03894-z.
|
| 39. |
Chakraborty S, Sheth JU, Ganguly S, et al. Efficacy and safety of intravitreal brolucizumab in chronic central serous chorioretinopathy: a retrospective cohort study[J]. Clin Ophthalmol, 2025, 19: 3557-3565. DOI: 10.2147/OPTH.S550375.
|
| 40. |
Feo A, Abraham N, Mafi M, et al. Recalcitrant peripapillary pachychoroid syndrome responds to high-dose aflibercept therapy[J/OL]. Retin Cases Brief Rep, 2025, 2025: E1(2025-09-11)[2026-01-05]. https://pubmed.ncbi.nlm.nih.gov/40927819/. DOI: 10.1097/ICB.0000000000001620. [published online ahead of print].
|
| 41. |
Chen R, Zhao Z, Yusufu M, et al. Choroidal vascular fingerprints from indocyanine green angiography unveil chorioretinal disease state[J/OL]. Invest Ophthalmol Vis Sci, 2025, 66(13): 3[2025-10-01]. https://pubmed.ncbi.nlm.nih.gov/41031739/. DOI: 10.1167/iovs.66.13.3.
|
| 42. |
Demirel S, Ellialtio?lu PA, Yan?k ?, et al. Non-indocyanine green angiography non-invasive differentiating features in the differential diagnosis of pachychoroid neovascularopathy and neovascular age-related macular degeneration: a sensitivity-specificity study[J]. Eye (Lond), 2025, 39(17): 3090-3098. DOI: 10.1038/s41433-025-04039-y.
|
| 43. |
Frederiksen IN, Arnold-Vangsted A, Anguita R, et al. Global incidence of central serous chorioretinopathy: a systematic review, meta-analysis, and forecasting study[J]. Ophthalmol Ther, 2025, 14(10): 2443-2467. DOI: 10.1007/s40123-025-01220-0.
|
| 44. |
Moon K, Kwon H, Jeon S. Anatomic changes in asymptomatic pachychoroid spectrum diseases after cataract surgery[J/OL]. Sci Rep, 2024, 14(1): 21247[2024-09-11]. https://pubmed.ncbi.nlm.nih.gov/39261655/. DOI: 10.1038/s41598-024-72444-6.
|